A volatile stock market represents an ideal opportunity for long-term investors to pounce.It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related uncertainty pushed the Nasdaq Composite into its first bear market in three years, and weighed the S&P 500 down to near-bear market territory.Historic ...

The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines. If you’re the kind of investor to plan for the long run, strapping in with some value stocks is definitely the way to go amid shifting interest rate expectations and trade tensions.Accordingly, we’ve pinpointed two companies with promising fundamentals that you should consider in the following months.1. Berkshire Hathaway (NYSE: BRK.B) Berkshire Hathaway (NYSE: BRK.B), t ...

Investors in BioMarin Pharmaceutical Inc. (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 18, 2025 $40.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. I ...

Group 1: Acquisition Details - BioMarin Pharmaceutical (BMRN) has entered into a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00 per share, totaling nearly $270 million [1] - The acquisition is expected to close in the third quarter of 2025, following approval from the boards of both companies [1] Group 2: Strategic Fit and Pipeline Expansion - The acquisition will add Inozyme's lead asset, INZ-701, to BioMarin's pipeline, which is an investigational enzyme replacement therapy for ENPP1 deficiency, a rare genetic disorder [2][3] - INZ-701 is currently in a pivotal late-stage study, with interim results expected in early 2026 and potential regulatory approval in 2027 [3] Group 3: Market Impact and Stock Performance - Following the acquisition announcement, shares of Inozyme surged by 178%, while BioMarin's shares gained about 2% [5] - Year-to-date, BioMarin's shares have decreased by 10%, whereas Inozyme's shares have increased by 43% [5] Group 4: Benefits of the Acquisition - The deal is seen as a strategic fit for BioMarin, which already markets five first-in-disease enzyme therapies, thus expanding its Enzyme Therapies portfolio and diversifying revenue streams [6] - Inozyme benefits from the acquisition as it lacks the commercial infrastructure to bring a drug to market, an area where BioMarin is well established [8] Group 5: Financial Guidance - BioMarin has reaffirmed its full-year 2025 sales guidance of $3.1-$3.2 billion and adjusted EPS guidance of $4.20-$4.40 [8]

Summary of BioMarin Pharmaceutical (BMRN) Conference Call Company and Industry - **Company**: BioMarin Pharmaceutical - **Industry**: Biotechnology, specifically focused on enzyme therapies for rare genetic conditions Key Points and Arguments 1. **Acquisition Announcement**: BioMarin announced the acquisition of Innozyme Pharma, focusing on the investigational enzyme therapy INZ-701 for treating ENPP1 deficiency, a rare genetic condition [5][9][66] 2. **Strategic Fit**: The acquisition aligns with BioMarin's enzyme therapies business unit, leveraging its regulatory, manufacturing, and commercialization capabilities [5][6][19] 3. **Product Profile**: INZ-701 is positioned as a first-in-disease treatment for ENPP1 deficiency, with a pivotal Phase III study expected to read out in early 2026 and potential regulatory approval in 2027 [6][10][66] 4. **Market Potential**: The total addressable patient population for ENPP1 deficiency is estimated to be between 2,000 to 2,500, with peak revenues projected between $400 million and $600 million by the mid-2030s [8][10][31] 5. **Financial Impact**: The acquisition cost is approximately $270 million, which BioMarin believes is capital efficient and will not significantly deplete its financial resources [9][19][29] 6. **Growth Strategy**: BioMarin aims to continue pursuing business development opportunities to supplement its growth outlook, indicating a favorable environment for further acquisitions [18][19][66] 7. **Pediatric and Adult Studies**: The pediatric population represents about 30% of the total prevalent population, with a focus on bringing INZ-701 to both pediatric and adult patients [31][48] 8. **Regulatory Engagement**: BioMarin plans to engage with regulators to discuss potential accelerated development pathways for both pediatric and adult populations [37][56] Other Important Content 1. **Antidrug Antibodies (ADAs)**: High rates of ADAs have been observed in infants, but management strategies are in place to address this issue [61][64] 2. **Overlap with Current Prescribers**: There is a significant overlap between prescribers of BioMarin's existing therapies and those for Innozyme's products, which could facilitate market entry [59] 3. **Non-GAAP Financial Measures**: The call included discussions on non-GAAP financial measures, emphasizing the importance of these metrics in evaluating financial performance [2][3] This summary captures the essential details from the conference call regarding BioMarin's acquisition of Innozyme Pharma and the strategic implications for the company's future in enzyme therapies.

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 DeficiencyFirst Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 DeficiencyConference Call and Webcast Scheduled Today at 8:45 a.m. ETSAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. ...

BioMarin Pharmaceutical (BMRN) reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of 94 cents. Quarterly earnings rose 59% year over year, driven by higher product sales and lower operating expenses.Total revenues were $745 million, which rose 15% year over year on a reported basis and 17% on a constant-currency basis. The top line beat the Zacks Consensus Estimate of $737 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-26727 ________________________ ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.21%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.73 per share when it actually produced earnings of $0.92, delivering a surprise of 26.03%.Over the l ...

BioMarin Pharmaceutical (BMRN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the BioMarin Pharmaceutical First Quarter twenty twenty five Conference Call. Just a reminder that this conference is being recorded. I would now like to hand things over to Ms. Tracy McCarty. Please go ahead, ma'am. Speaker1 Thank you, operator. To remind you, this non confidential presentation contains forward looking statements about the business prospects of BioMarin Pharmaceutical I ...